Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treatment with Anti-vegf antibodies

a technology of anti-vegf antibodies and anti-cancer drugs, applied in the direction of cardiovascular disorders, drug compositions, peptides, etc., can solve the problems of numerous side effects, difficult detection and treatment, and current cancer treatment methods that are relatively non-selectiv

Inactive Publication Date: 2007-02-01
GENENTECH INC
View PDF1 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0016] Accordingly, in one aspect, the invention provides a method of treating cancer in a human patient, comprising administering to the patient effective amounts of an anti-VEGF antibody and an anti-neoplastic composition, wherein said anti-neoplastic composition comprises at least one chemotherapeutic agent.
[0022] In yet another aspect, the present invention provides a method for increasing the duration of response of a human patient having cancer, comprising administering to the patient effective amounts of an anti-VEGF antibody composition and an anti-neoplastic composition, wherein said anti-neoplastic composition comprises at least one chemotherapeutic agent, whereby the co-administration of the anti-VEGF antibody and the anti-neoplastic composition effectively increases the duration of response.

Problems solved by technology

Cancers, or malignant tumors, metastasize and grow rapidly in an uncontrolled manner, making timely detection and treatment extremely difficult.
Current methods of cancer treatment are relatively non-selective.
Chemotherapy, in particular, results in numerous side effects, in some cases so severe as to limit the dosage that can be given and thus preclude the use of potentially effective drugs.
Moreover, cancers often develop resistance to chemotherapeutic drugs.
Delivery of oxygen and nutrients, as well as the removal of catabolic products, represent rate-limiting steps in the majority of growth processes occurring in multicellular organisms.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment with Anti-vegf antibodies
  • Treatment with Anti-vegf antibodies
  • Treatment with Anti-vegf antibodies

Examples

Experimental program
Comparison scheme
Effect test

example 1

Addition of an Anti-VEGF Antibody to Bolus Irinotecan / Fluorouracil / Leucovorin (IFL) in First Line Metastatic Colorectal Cancer

[0193] A multicenter, Phase III, randomized, active-controlled trial was conducted to evaluate the efficacy and safety of bevacizumab when added to standard first-line chemotherapy used to treat metastatic colorectal cancer. The trial enrolled over 900 patients with histologically confirmed, previously untreated, bi-dimensionally measurable metastatic colorectal cancer.

Methods and Materials

Anti-VEGF Antibody bevacizumab

[0194] The anti-VEGF antibody “Bevacizumab (BV)”, also known as “rhuMAb VEGF”or “Avastin™”, is a recombinant humanized anti-VEGF monoclonal antibody generated according to Presta et al. (1997) Cancer Res. 57:4593-4599. It comprises mutated human IgG1 framework regions and antigen-binding complementarity-determining regions from the murine anti-hVEGF monoclonal antibody A.4.6.1 that blocks binding of human VEGF to its receptors. U.S. Pat. ...

example 2

Addition of Bevacizumab to Bolus 5-FU / Leucovorin in First-Line Metastatic Colorectal Cancer

[0227] This randomized, phase II trial compared bevacizumab plus 5-fluorouracil and leucovorin (5-FU / LV) versus placebo plus 5-FU / LV as first-line therapy in patients considered non-optimal candidates for first-line irinotecan.

Patients and Methods

Patient Eligibility

[0228] Patients with histologically confirmed, previously untreated, measurable metastatic colorectal cancer were eligible if, in the judgment of the investigator, they were not optimal candidates for first-line irinotecan-containing therapy and had at least one of the following characteristics: age above 65 years, ECOG PS of 1 or 2, serum albumin equal or less than 3.5 g / dL, or prior radiotherapy to abdomen or pelvis. Patients were excluded if they had undergone major surgical procedures or open biopsy, or had experienced significant traumatic injury, within 28 days prior to study entry; anticipated need for major surgery dur...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
sizeaaaaaaaaaa
molecular massaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.

Description

[0001] This is a continuation application claiming priority to U.S. application Ser. No. 10 / 857,249, filed May 28, 2004, which claims the benefit of U.S. provisional Application No. 60 / 474,480, filed May 30, 2003, the contents of which applications are incorporated herein by reference.FIELD OF THE INVENTION [0002] This invention relates in general to treatment of human diseases and pathological conditions. More specifically, the invention relates to anti-angiogenesis therapy of cancer, either alone or in combination with other anti-cancer therapies. BACKGROUND OF THE INVENTION [0003] Cancer remains to be one of the most deadly threats to human health. In the U.S., cancer affects nearly 1.3 million new patients each year, and is the second leading cause of death after heart disease, accounting for approximately 1 in 4 deaths. It is also predicted that cancer may surpass cardiovascular diseases as the number one cause of death within 5 years. Solid tumors are responsible for most of t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61K38/48A61K38/09A61K38/21A61K31/7048A61K31/704A61K31/522A61K31/56A61K31/513A61K31/4745A61K31/525A61K31/7072A61K45/06A61P35/00A61P35/04C07K16/22
CPCA61K45/06C07K2317/24A61K31/522A61K31/525A61K31/573A61K38/09A61K38/212A61K38/50A61K39/39541A61K39/3955C07K16/22A61K31/555A61K39/39558A61K31/337A61K31/4745A61K31/7068A61K31/282A61K31/4545A61K31/513A61K31/519A61P31/00A61P35/00A61P35/02A61P35/04A61P43/00A61P9/00A61K2300/00A61K39/395A61K2039/505A61K9/0019C07K16/3046C07K2317/21C07K2317/565C07K2317/567C07K2317/76
Inventor FYFE, GWENDOLYNHOLMGREN, ERICMASS, ROBERTNOVOTNY, WILLIAM
Owner GENENTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com